This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Palevsky, H. I. Articles by Fishman, A. P. Search for Related Content PubMed PubMed Citation Articles by Palevsky, H. I. Articles by Fishman, A. P.

Circulation, Vol 82, 2018-2026, Copyright © 1990 by American Heart Association

ARTICLES

Prostacyclin and acetylcholine as screening agents for acute pulmonary vasodilator responsiveness in primary pulmonary hypertension

HI Palevsky, W Long, J Crow and AP Fishman
Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia.

Epoprostenol sodium (prostacyclin) administered intravenously is considered the standard for assessing the ability of the pulmonary circulation to vasodilate. At present, epoprostenol sodium is an investigational drug that has limited availability. In contrast, acetylcholine, also a pulmonary vasodilator, is readily available. Therefore, we assessed the feasibility of using acetylcholine as an alternative to prostacyclin in testing for the capacity of the pulmonary vasculature to vasodilate. Twenty-three patients with primary pulmonary hypertension (mean pulmonary arterial pressure, 58.5 +/- 13.4 mm Hg) received incremental infusions of prostacyclin and acetylcholine to predetermined maximal infusion rates as part of a battery of vasodilator agents administered according to standard protocols (mean, 5.4 +/- 1.2 agents/patient; range, 3-8 agents/patient); the administration of the different agents was timed to avoid synergistic effects. Of all the agents tested, prostacyclin and acetylcholine were most consistently effective in evoking acute pulmonary vasodilation, and both seemed to distinguish patients capable of manifesting acute pulmonary vasodilation from those who were not. However, at maximal doses set by protocol, prostacyclin generally elicited a greater vasodilator response than acetylcholine. The difference in magnitude of response may have been due to use of prescribed dosages of acetylcholine that were submaximal. In other respects, the two agents were similar; both were equally well-tolerated, and side effects were mild and resolved rapidly when the vasodilator infusions were stopped. We conclude that in the majority of patients with primary pulmonary hypertension, acetylcholine appears to be an effective and available substitute for prostacyclin in screening for pulmonary vasodilator responsiveness.

This article has been cited by other articles:

				D. Chemla, V. Castelain, P. Herve, Y. Lecarpentier, and S. Brimioulle Haemodynamic evaluation of pulmonary hypertension Eur. Respir. J., November 1, 2002; 20(5): 1314 - 1331. [Abstract] [Full Text] [PDF]

				G. Cremona, T. W. Higenbottam, E. A. Bower, A. M. Wood, and S. Stewart Hemodynamic Effects of Basal and Stimulated Release of Endogenous Nitric Oxide in Isolated Human Lungs Circulation, September 21, 1999; 100(12): 1316 - 1321. [Abstract] [Full Text] [PDF]

				H. S. Mueller, K. Chatterjee, K. B. Davis, M. A. Fifer, C. Franklin, M. A. Greenberg, A. J. Labovitz, P. K. Shah, K. J. Tuman, M. H. Weil, et al. Present use of bedside right heart catheterization in patients with cardiac disease J. Am. Coll. Cardiol., September 1, 1998; 32(3): 840 - 864. [Full Text] [PDF]

				C. DEFOUILLOY, E. TEIGER, S. SEDIAME, P. ANDRIVET, F. ROUDOT-THORAVAL, C. CHOUAID, B. HOUSSET, and S. ADNOT Polycythemia Impairs Vasodilator Response to Acetylcholine in Patients with Chronic Hypoxemic Lung Disease Am. J. Respir. Crit. Care Med., May 1, 1997; 157(5): 1452 - 1460. [Abstract] [Full Text]

				O. Raffy, R. Azarian, F. Brenot, F. Parent, O. Sitbon, P. Petitpretz, P. Herve, P. Duroux, A. T. Dinh-Xuan, and G. Simonneau Clinical Significance of the Pulmonary Vasodilator Response During Short-term Infusion of Prostacyclin in Primary Pulmonary Hypertension Circulation, February 1, 1996; 93(3): 484 - 488. [Abstract] [Full Text]

				M. R. Costanzo, S. Augustine, R. Bourge, M. Bristow, J. B. O'Connell, D. Driscoll, and E. Rose Selection and Treatment of Candidates for Heart Transplantation : A Statement for Health Professionals From the Committee on Heart Failure and Cardiac Transplantation of the Council on Clinical Cardiology, American Heart Association Circulation, December 15, 1995; 92(12): 3593 - 3612. [Abstract] [Full Text]